Nurix Therapeutics (NRIX) Fundamental Analysis: Revenue, Earnings & Valuation

3.86 / 10

Netural

Fundamental analysis rates NRIX as Neutral with a low composite score of 3.86. Profit‑MV and Cash‑MV are positive, but Asset‑MV is negative and Current‑assets turnover is weak. Gross margin is high (100%) while income‑tax ratio drags performance.

Analysis Checks(7/10)

Revenue-MV

Value-2.66

Score1/3

Weight12.59%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight15.29%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.24%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight14.38%

1M Return6.36%

Income tax / Total profit (%)

Value-0.29

Score1/3

Weight0.35%

1M Return0.21%

Current assets turnover ratio

Value0.14

Score0/3

Weight-2.68%

1M Return-1.61%

Fixed assets turnover ratio

Value1.41

Score2/3

Weight0.02%

1M Return0.01%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight7.60%

1M Return4.08%

Asset-MV

Value-0.55

Score2/3

Weight35.13%

1M Return13.10%

Cash-MV

Value0.03

Score2/3

Weight14.09%

1M Return6.19%

Is NRIX fundamentally strong?

NRIX scores 3.86/10 on fundamentals and holds a Fair valuation at present. Backed by its -49.63% ROE, -314.90% net margin, -6.00 P/E ratio, 2.95 P/B ratio, and -5.90% earnings growth, these metrics solidify its Netural investment rating.